Immutep is listed on the Australian Stock Exchange (ASX:IMM) and on the NASDAQ Global Market (NASDAQ:IMMP) in the U.S. (ADR's).
We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.
We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.
Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.
Interviews /
by Paul Sanger -
A year ago
31 Oct 2023 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Co…
Company News /
by Abbey Phillipps -
A year ago
23 Oct 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM; NASDAQ:IMMP), Chimeric Therapeutics (ASX:CHM) and Sayona Mining (ASX:SYA; OTCQB:SYAXF).
Company News /
by Peter Milios -
A year ago
31 Jul 2023 - Immunotherapy company Immutep has released its Quarterly Activities report, which highlights significant progress in late-stage and registrational trials.
Market Reports /
by Peter Milios -
A year ago
28 Jul 2023 - Australian retail sales experienced a 0.8% decline last month, as reported by the Australian Bureau of Statistics. This result came as a surprise to markets, which ha…
Company News /
by Peter Milios -
A year ago
20 Jun 2023 - Immutep Limited (ASX:IMM), a clinical-stage biotechnology company focusing on LAG-3 immunotherapies for cancer and autoimmune diseases, has received a new patent from…
Market Reports /
by Peter Milios -
A year ago
24 May 2023 - At the closing bell, the S&P/ASX 200 was 0.63 per cent lower at 7,213.80. This drop was primarily influenced by the materials and healthcare sectors.
Market Reports /
by Peter Milios -
A year ago
24 May 2023 - Swiss banks UBS and Credit Suisse are nearing the completion of their merger, with regulatory approval expected by 31 May.
Interviews /
by Paul Sanger -
A year ago
19 May 2023 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the significance of recent announcements on the back of a surge in trading volume.
Market Reports /
by Peter Milios -
A year ago
18 May 2023 - At the closing bell, the S&P/ASX 200 was 0.52 per cent higher at 7,236.80. Nufarm's (ASX:NUF) shares rallied 14.2 per cent to $6.05 after announcing a 7 per cent incr…
Market Reports /
by Peter Milios -
A year ago
18 May 2023 - According to the Australian Bureau of Statistics, the economy experienced a loss of 4,300 jobs in the previous month, which was contrary to economists' predictions of…
Market Reports /
by Peter Milios -
A year ago
16 May 2023 - On Tuesday, at the closing bell, the S&P/ASX 200 was 0.45 per cent lower at 7,234.70, as the healthcare, tech, and consumer staples sectors witnessed drops, which cou…
Market Reports /
by Peter Milios -
A year ago
16 May 2023 - The Reserve Bank's minutes for May indicate that the central bank is committed to reducing inflation. The Board expressed its determination to take the necessary acti…
Market Reports /
by Peter Milios -
2 years ago
17 Apr 2023 - At the closing bell, the S&P/ASX 200 was 0.27 per cent higher at 7,381.50, led by gains in the financials and real estate sectors.
Market Reports /
by Peter Milios -
2 years ago
17 Apr 2023 - Nine out of the eleven sectors are trading higher today. Information technology is surging on the back of gains from WiseTech Global (ASX:WTC), Xero (ASX:XRO), and Al…
